Industry’s Newest Generation IRT Fuels Growth of Almac Group’s Business

Industry’s Newest Generation IRT Fuels Growth of Almac Group’s Business

October 12, 2015

A Majority of Top 15 Pharmaceutical Companies Have Committed to Using IXRS® 3 Across Development Programs

Souderton, PA., USA,  – 12 October 2015 − Almac Clinical Technologies, part of the Almac Group, a global leader in technology for managing clinical trial patients and supplies, is continuing to grow on the strength of its newest solution: IXRS® 3. Less than a year after launching the company’s latest generation Interactive Response Technology (IRT), a majority of the industry’s top 15 biopharmaceutical companies have committed to adopting the IXRS 3 platform.

Concurrently, Almac has seen consistent growth in demand for deployment of new programs among leading Contract Research Organizations (CROs) seeking a technology partner that shares the vision of long-term success through quality and stability.   Due to this uptake, Almac is seeking to attract additional top talent to its existing roster of experts in the eClinical solutions space.

President and Managing Director of Almac Clinical Technologies, Valarie Higgins, relates the overwhelming market response and subsequent expansion of the business to the need for greater efficiencies throughout the clinical development process, and the supply chain in particular. “Operational success is increasingly dependent upon a company’s focus on innovation and its ability to rely on technology partners to consistently deliver high quality data,” Valarie maintained. “I am also proud to report that due to this growth, we are actively hiring.  We have a robust team of experts in place and are now looking to hire more of the brightest minds in the industry.”

A Pre-Configured Core that is Easily Customized

IXRS 3 is designed to automate daily tasks for investigator sites, sponsors and CROs in the management of patient events and drug inventory throughout the lifecycle of clinical trials. The proprietary software is pre-configured with the features and functions that most trials require, while the underlying architecture makes it easy to customize quickly for any given sponsor, program or trial.

“IXRS 3 is all about solving complexity challenges and providing real-time control of protocol execution.” explains Valarie. “And that begins with rapid deployment. In the past, trial timelines could derail because of the complexity involved in configuring and adjusting the technology. But, no more. We’ve struck the perfect balance between features and functions that are built-in and those that can—and should—be bespoke for each installation. And that saves time and money in the development phase.”

Role-Specific Access and Capabilities

IXRS 3 is readily configurable—both at start up and as the study progresses—and caters to the needs of various different user types within sponsor organizations, CROs and trial sites. Self-service features allow users to change settings as befits their role and responsibilities without having to ask Almac support services for help. The system includes personalized services for:

  • Investigator Sites. The site-facing tool is unobtrusive, yet simplifies patient activities and automate steps that are prone to human error.
  • Supply Chain Managers. The system provides alerts and re-supply options to keep product supplies at optimum levels.
  • Study Management Teams. At-a-glance trial metrics and alerts help monitors prepare for site visits.
  • Clinical Operations. Easy-to-read dashboards show key patient metrics in real time to support constant performance monitoring.
  • Data Managers. Real-time data replication and pre-built integrations with leading EDC and CTMS contribute to higher quality source data—and fewer data discrepancies.
  • R&D Leaders. Sophisticated delivery and relationship management processes ensure compliance, ease the burden of vendor oversight and minimize the amount of training required.

Ongoing Innovation and Economies of Scale

When IXRS 3 is used alongside Almac’s services in product packaging, labeling, distribution, reconciliation and destruction, sponsors benefit from seamless alignment across all interdependencies in the global supply chain. “By synchronizing the digital and physical supply chains in a closed-loop system, companies gain optimal visibility and efficiency,” added Valarie. “We’re able to engineer out costs, bake in standards and improve processes and system functionality.

To find out more, please visit our website at www.almacgroup.com.

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organization that has organically grown over 40 years and now employs in excess of 3,900 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

For more information visit www.almacgroup.com or e-mail media@almacgroup.com.

Share

Back to news